'On consolidated basis
Quarter ended June 2025 compared with Quarter ended June 2024.
Net sales (including other operating income) of Aurobindo Pharma has increased 3.98% to Rs 7868.14 crore. Operating profit margin has declined from 21.40% to 20.37%, leading to 1.02% decline in operating profit to Rs 1,603.03 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 32.28% to 31.80%. Purchase of finished goods cost rose from 8.90% to 10.13%. Employee cost increased from 14.03% to 15.41%. Other expenses fell from 23.59% to 22.54%.
Other income fell 52.34% to Rs 105.3 crore. PBIDT fell 7.18% to Rs 1708.33 crore. Provision for interest fell 11.97% to Rs 97.75 crore.
PBDT fell 6.87% to Rs 1610.58 crore. Provision for depreciation rose 0.38% to Rs 405.7 crore.
Profit before tax down 9.08% ...
Pleaselogin & subscribe to view the full report.
More Reports
|
|